Gastrointestinal safety of COX-2 specific inhibitors

Gastroenterology Clinics of North America

Volumn 30, Issue 4, 2001, Pages 921-936

  Hawkey, Christopher J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGING; ANTICOAGULANT THERAPY; ARTHRITIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIGESTIVE SYSTEM ULCER; DYSPEPSIA; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HEART FAILURE; HELICOBACTER PYLORI; HUMAN; HYPERTENSION; INFLAMMATION; PAIN; PROSTAGLANDIN SYNTHESIS; REVIEW; RISK FACTOR; VASCULAR DISEASE;

EID: 0035202042     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(05)70220-X     Document Type: Article

References (80)

1. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users: Response to omeprazole dual therapy
2. A double-blind comparison of rofecoxib and naproxen on the incidence of clinically important upper gastrointestinal events: The VIGOR trial
3. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
4. Celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis
5. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition
6. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study
7. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
8. Ranitidine: Differential effects on gastric bleeding and mucosal damage induced by aspirin
9. In vivo effects of rofecoxib, a new cyclooxygenase (COX)-2 inhibitor, on gastric mucosal prostaglandin (PG) and serum thromboxane B2 (TBX2) synthesis in healthy humans
10. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans
11. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
12. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis
13. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
14. Ocular safety of antiulcer drugs
15. Influence of H. pylori (Hp) infection and/or low dose aspirin (aASA) on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDs
16. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: Interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications - Future research needs
17. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
18. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates
19. Effect of rofecoxib on endoscopic ulcers in osteoarthritis patients: Analysis of potential risk factors
20. Non-steroidal anti-inflammatory drugs and peptic ulcers: Facts and figures multiply, but do they add up?
21. Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance
22. Outcomes studies of drug induced ulcer complications: Do we need them and how should they be done?
23. Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach
24. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs
25. Relative contribution of MI and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs
26. Helicobacter pylori eradication in patients taking non-steroidal, anti-inflammatory drugs: The HELP NSAIDs study
27. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
28. Men are from Mars, women are from Venus: Influence of sex and H. pylori on development and healing of gastroduodenal lesions in NSAID users
29. NSAID ulcers tend to recur at original site: Differential effects of Helicobacter pylori
30. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
31. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s
32. Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study
33. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: A case-control study
34. Angiogenesis in gastric ulcers: Imparied in patients taking non-steroidal anti-inflammatory drugs
35. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking nonsteroidal anti-inflammatory drugs
36. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells
37. Gastrointestinal consequences of treatment with drugs in elderly patients
38. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
39. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
40. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
41. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer
42. Stratifying the risk of clinical upper GI events in NSAID users: Results from a double-blind outcomes study
43. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
44. Risks of bleeding peptic ulcer associate with individual non-steroidal anti-inflammatory drugs
45. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
46. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
47. Flexibility of the NSAID binding site in the structure of human cyclooxygenase- 2
48. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic
49. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
50. Age does not influence acute aspirin-induced gastric mucosal damage
51. Portal venous transfusion up-regulates Kupffer cell cyclooxygenase activity: A mechanism of immunosuppression in organ transplantation
52. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
53. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs
54. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor
55. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays
56. Rofecoxib
57. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
58. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants place elderly persons at high risk for hemorrhagic peptic ulcer disease
59. Gastrointestinal toxicity with celecoxib vs nonsteroida anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
60. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
61. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study
62. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons
63. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer
64. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
65. Aspirin, NSAIDs, and digestive tract cancers
66. Aspirin use and reduced risk of fatal colon cancer
67. Quantitative estimation of rare adverse events which follow a biological progression: A new model applied to chronic NSAID use
68. Mediators of the anaphylactic reaction
69. The mechanism of action of anti-inflammatory drugs
70. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
71. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
72. Peptic ulcer bleeding: Accessory risk factors and interactions with non-steroidal anti-inflammatory drugs
73. Rofecoxib, COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production
74. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
75. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
76. The nonsteroidal anti-inflammatory drugs controversy
77. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs
78. Aspirin protects against gastric cancer: Results of a case-control study from Moscow, Russia